Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
25 participants
INTERVENTIONAL
2023-04-28
2023-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275
Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation
NCT02172508
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
NCT01525615
Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172391
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
NCT01533922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Order: Period A, Period B, Period C
The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Period A
Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period B
Week 1: AD816 low dose; Week 2: AD816 high dose
Period C
Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Order: Period B, Period C, Period A
The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Period A
Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period B
Week 1: AD816 low dose; Week 2: AD816 high dose
Period C
Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Order: Period C, Period A, Period B
The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Period A
Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period B
Week 1: AD816 low dose; Week 2: AD816 high dose
Period C
Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Order: Period A, Period C, Period B
The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Period A
Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period B
Week 1: AD816 low dose; Week 2: AD816 high dose
Period C
Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Order: Period B, Period A, Period C
The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Period A
Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period B
Week 1: AD816 low dose; Week 2: AD816 high dose
Period C
Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Order: Period C, Period B, Period A
The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Period A
Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period B
Week 1: AD816 low dose; Week 2: AD816 high dose
Period C
Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Period A
Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
Period B
Week 1: AD816 low dose; Week 2: AD816 high dose
Period C
Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. PSG criteria (V2 only)
1. AHI4 (Hypopneas defined by 4% oxygen desaturation) of 10-45, inclusive
2. ≤25% of events are central or mixed apneas
3. PROMIS Fatigue or sleep related impairment or sleep disturbance (raw score): \>11, i.e. at least "very mild symptoms" at V1
4. BMI between 18.5 and 40 kg/m2, inclusive
Male participants:
5. If sexually active with female partner(s) of childbearing potential, participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified contraception
Female participants:
6. If of childbearing potential (WOCBP), the participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified contraception. All WOCBP must have negative result of a serum pregnancy test performed at screening.
a. Females of non-childbearing potential include postmenopausal (defined as age ≥ 55 years with no menses for 12 or more months without an alternative medical cause) or permanently sterile (e.g. bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
7. Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the Screening Visit procedures.
8. Participant must be able to understand the nature of the study and must have the opportunity to have any questions answered
Exclusion Criteria
2. Clinically significant craniofacial malformation or grade ≥3 tonsillar hypertrophy.
3. Current clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or poorly controlled hypertension (\>140/90mmHg).
4. Long QT syndrome or family history of long QT syndrome
5. Current clinically significant neurological disorder, including epilepsy/convulsions.
6. Other active major organ system disease including renal failure, lung disease, neuromuscular disease, or liver disease.
7. Schizophrenia, schizoaffective disorder or bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) or International Classification of Disease tenth edition criteria.
8. Attempted suicide within 1 year prior to screening, or current suicidal ideation.
9. Clinically significant urinary retention, gastric retention or other severe decreased gastrointestinal motility condition.
10. Benign prostatic hypertrophy that is actively being treated with alpha-1 adrenergic antagonist
11. Severe or frequent gastroesophageal reflux or constipation
12. Medically unexplained positive screen for drugs of abuse (excluding THC/marijuana) or history of substance use disorder as defined in DSM-V within 24 months prior to Screening Visit.
13. A serious illness or infection in the past 30 days as determined by investigator.
14. Clinically significant cognitive dysfunction as determined by investigator.
15. Untreated narrow angle glaucoma.
16. Women who are pregnant or nursing.
17. CPAP should not be used for at least 2 weeks prior to first study PSG and during entire participation in the study.
18. History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used for at least 2 weeks prior to first study PSG and during participation in the study.
19. History of using devices to affect participant sleeping position for the treatment of OSA, e.g. to discourage supine sleeping position, may enroll as long as the devices are not used for at least 2 weeks prior to first study PSG and during participation in the study.
20. Chronic oxygen therapy.
21. Patients with hypoglossal nerve stimulation implant. Prior/Concurrent Clinical Study Experience
22. Use of another investigational agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.
23. Prolonged QT interval (\> 450 ms in men or \> 470 ms in women, after correction with most appropriate formula for observed heart rate), hypokalemia or hypomagnesemia (defined as \>0.1 mEq/L below lower limit of normal for the testing laboratory).
24. Hepatic transaminases \>2X the upper limit of normal (ULN), total bilirubin \>1.5X ULN (unless confirmed Gilbert syndrome), estimated glomerular filtration rate \< 50 ml/min.
25. Night- or shift-work sleep schedule which causes the major sleep period to be during the day, or planned travel across more than 1 time zone during the anticipated enrollment period
26. Employment as a commercial driver or operator of hazardous equipment.
27. Typically smoking more than 10 cigarettes or 2 cigars per day (or equivalent Vaping), or inability to abstain from smoking during overnight PSG visits.
28. Unwilling to use specified contraception.
29. History of regular alcohol consumption of more than 14 standard units per week (males) or more than 7 standard units per week (females), or unwillingness to limit alcohol consumption to no greater than 2 units/day (males), 1 unit per day (females). Alcohol is not to be consumed within 3 hours of bedtime or on PSG nights.
30. Unwilling to agree to limit during the study period caffeinated beverage intake (e.g., coffee, cola, tea) to 200 mg/day or less of caffeine, not to be used within 3 hours of bedtime. Viloxazine may increase the duration of effect of caffeine.
31. Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.
32. Participant considered by the investigator, for any reason, an unsuitable candidate to receive viloxazine or AD816 components, or unable or unlikely to understand or comply with the dosing schedule or study evaluations.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Apnimed
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald Farkas, MD
Role: STUDY_DIRECTOR
Apnimed Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Santa Monica Clinical Trials
Los Angeles, California, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Clayton Sleep Institute
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Aishah A, Kim M, Gell L, Vena D, Azarbarzin A, Pho H, Norman D, Ojile J, Esmaeili N, Taranto-Montemurro L, Wellman A, Sands S, Messineo L. Effect of viloxazine and trazodone in obstructive sleep apnoea: a randomised, placebo-controlled, cross-over study. Thorax. 2025 Aug 15;80(9):641-649. doi: 10.1136/thorax-2024-222513.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APV-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.